Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 229-222-8 | CAS number: 6440-58-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-1 (90-Day Oral Toxicity)
- Deviations:
- yes
- Remarks:
- No measure of clotting potential, histopathology conducted on first 10 necropsied of the 15 animals/sex/dose group.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 5,5-dimethylhydantoin
- EC Number:
- 201-051-3
- EC Name:
- 5,5-dimethylhydantoin
- Cas Number:
- 77-71-4
- Molecular formula:
- C5H8N2O2
- IUPAC Name:
- 5,5-dimethylimidazolidine-2,4-dione
- Details on test material:
- The test material is the hydrolysis degradation product of DMDMH which was considered relevant for long term testing
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- 5 days per week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
100 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
300 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
1000 mg/kg
Basis:
actual ingested
- No. of animals per sex per dose:
- 15/ per sex/dose
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Detailed clinical examination made weekly, observation at least once per day.
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION: Yes
- Time schedule: Weekly
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Prior to study initiation and during final week of study
HAEMATOLOGY: Yes
- Time schedule for collection of blood: end of study
- Number of animals: First ten surviving animals/sex/group examined at necropsy
- Parameters: Haematocrit, haemoglobin concentration, erythrocyte count, total and differential leukocyte count, platelet count.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: end of study
- Number of animals: First ten surviving animals/sex/group examined at necropsy
- Parameters: sodium, potassium, chloride, glucose, calcium, globulin (calculated), blood urea nitrogen, total bilirubin, creatinine, total protein, albumin, alanine aminotransferase, aspartate aminotransferase, phosphorous, alkaline phosphatase, gamma glutamyl transferase, A/G ratio (calculated)
URINALYSIS: No - Sacrifice and pathology:
- Organ Weights - Liver, kidneys, adrenals, testes, ovaries, brain with stem
Gross and histopathology - Gross necropsy performed on all animals surviving to termination. Hisptopathology performed on first 10 surviving animals/sex/dose level exmined at necropsy in high dose group and controls as well as animals that succumbed prior to termination: brain, spinal cord, pituitary, thyroid, parathyroid, thymus, oesophagus, salivary glands, stomach, sternum with marrow, small and large intestines, liver, pancreas, kidneys, adrenals, spleen, heart, trachea, lungs, aorta, uterus, mammary glands, prostate, urinary bladder, lymph nodes, skin, eyes. Histopathology performed on first 10 surviving animals/sex/dose level in mid and low dose groups: Gross lesions, tissue masses, liver, lungs and kidney. - Statistics:
- Bartletts test was used to determine if dose groups had equal variance.
Parametric procedures used one way ANOVA using F distribution If significant differences were seen Dunnett’s test was used to determine which treatment groups differed significantly from the control.
For non parametric procedures test of equality of means was performed using Kruskal-Wallis test. If significant differences were seen Dunn’s Summed Rank test was used to determine which treatment groups differed significantly from the control.
In addition Jonckheere’s test for monotonic trend in the dose response was performed.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Sporadic occurrences of alopecia, missing/broken/maloccluded incisors and red/clear ocular discharge. One male in the control group was euthanized because of a broken snout. One female in the 300mg/kg dose group was found dead on due to mis dosing.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Sporadic occurrences of alopecia, missing/broken/maloccluded incisors and red/clear ocular discharge. One male in the control group was euthanized because of a broken snout. One female in the 300mg/kg dose group was found dead on due to mis dosing.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Decreased body weight gain in male rats in the high dose group. Increased body weight in females in all treatment groups.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Reduction in food consumption in the high dose male rats.
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- ORGAN WEIGHTS - The mean absolute and relative liver weights for male rats in the high dose group were decreased. The mean absolute and relative liver weigh values for females were increased in the high dose group. The mean absolute kidney weights were also increased in the high dose females but was considered to be a reflection of the increased body weight.
GROSS AND HISTOPATHOLOGY - Abnormalities noted at very low incidences included entire GI tract distended with gas, emaciation, smaller than normal seminal vesicles, clear yellow liquid in stomach, distended uterus, larger than normal ovaries, liver mass, liver thickening, lung discoloration and distended cecum. None of these appeared to be related to the treatment.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The NOAEL for DMH is >1000 mg/kg
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
